A Real-World Matched Cohort Study of the Effect of Concomitant Amiodarone or Diltiazem Administration on Apixaban Peak and Trough Concentrations
- 31 October 2022
- journal article
- research article
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 23 (1) , 59-66
Abstract
Background Apixaban is a substrate for p-glycoprotein and is extensively metabolized by cytochrome P450 (CYP) 3A4. There are minimal published data regarding the effect of amiodarone and diltiazem on apixaban serum concentrations. Objective The aim of this study was to determine the degree of elevation of apixaban concentrations resulting from amiodarone or diltiazem. Methods This was a matched cohort study approved by the Institutional Review Board. Patients receiving apixaban 5 mg twice daily with concomitant diltiazem or amiodarone were enrolled. Control groups were enrolled via matching characteristics of sex, age, weight, creatinine clearance, and statin therapy. Exclusions were an inappropriate dosage of apixaban or concomitant dronedarone, verapamil, ranolazine, naproxen, or both amiodarone and diltiazem. Blood samples were collected 3–4 h after and 0.5–2 h before an apixaban dose, corresponding to peak and trough concentrations, respectively. Results were compared using a t test. Results Thirty patients were enrolled in each of the four groups. The mean peak apixaban concentration was 239 ± 82 ng/mL in the amiodarone group and 208 ± 66 ng/mL in the corresponding control group (p = 0.068). Trough concentrations were 142 ± 71 ng/mL and 117 ± 41 ng/mL, respectively (p = 0.055). The mean peak apixaban concentration was 243 ± 99 ng/mL in the diltiazem group and 213 ± 82 ng/mL in the control group (p = 0.11). Trough concentrations were 130 ± 65 ng/mL and 108 ± 54 ng/mL, respectively (p = 0.09). Conclusion Coadministration of amiodarone and diltiazem resulted in a trend toward increased apixaban concentrations. The extent of elevation suggests that empiric dose changes are not necessary; however, individual patients may benefit from monitoring and dose adjustment.Keywords
This publication has 20 references indexed in Scilit:
- International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral AnticoagulantsThrombosis and Haemostasis, 2018
- Comparison of Anti-Xa Activity in Patients Receiving Apixaban or RivaroxabanAnnals of Pharmacotherapy, 2017
- Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine CareCanadian Journal of Cardiology, 2017
- Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES TrialTH Open, 2017
- Apixaban, concomitant medicines and spontaneous reports of haemorrhagic eventsTherapeutic Advances in Drug Safety, 2017
- Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillationThrombosis Research, 2015
- Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factorXa inhibitorBritish Journal of Clinical Pharmacology, 2014
- Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial FibrillationJACC, 2014
- Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assaysThrombosis and Haemostasis, 2014
- Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factorXa inhibitor, in healthy subjectsBritish Journal of Clinical Pharmacology, 2013